The dichotomous role of immunoproteasome in cancer: Friend or foe?
10.1016/j.apsb.2022.11.005
- Author:
Boya CHEN
1
;
Haiying ZHU
1
;
Bo YANG
1
;
Ji CAO
1
Author Information
1. Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
- Publication Type:Review
- Keywords:
Antigenic peptides;
Cancer;
Immunoproteasome;
Immunotherapy;
Proteasome inhibitor;
Proteolysis;
Targeted therapy;
Ubiquitin–proteasome system
- From:
Acta Pharmaceutica Sinica B
2023;13(5):1976-1989
- CountryChina
- Language:English
-
Abstract:
Immunoproteasome is a variant of proteasome with structural differences in 20S subunits optimizing them for the production of antigenic peptides with higher binding affinity to major histocompatibility complex (MHC)-I molecules. Apart from this primary function in antigen presentation, immunoproteasome is also responsible for the degradation of proteins, both unfolded proteins for the maintenance of protein homeostasis and tumor suppressor proteins contributing to tumor progression. The altered expression of immunoproteasome is frequently observed in cancers; however, its expression levels and effects vary among different cancer types exhibiting antagonistic roles in tumor development. This review focuses on the dichotomous role of immunoproteasome in different cancer types, as well as summarizes the current progression in immunoproteasome activators and inhibitors. Specifically targeting immunoproteasome may be a beneficial therapeutic intervention in cancer treatment and understanding the role of immunoproteasome in cancers will provide a significant therapeutic insight for the prevention and treatment of cancers.
